Testimonial

1. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999;156(5):675-682. PubMed 10327898 · doi:10.1176/ajp.156.5.675
2. Koenigs M, Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res. 2009;201(2):239-243. PubMed 19428640 · doi:10.1016/j.bbr.2009.03.004
3. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213(1-2):93-118. PubMed 18704495 · doi:10.1007/s00429-008-0189-x
4. Liston C, Chen AC, Zebley BD, et al. Default mode network mechanisms of transcranial magnetic stimulation in depression. Biol Psychiatry. 2014;76(7):517-526. PubMed 24629537 · doi:10.1016/j.biopsych.2014.01.023
5. Klomjai W, Katz R, Lackmy-Vallée A. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS). Ann Phys Rehabil Med. 2015;58(4):208-213. PubMed 26319963 · doi:10.1016/j.rehab.2015.05.005
6. O’Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208-1216. PubMed 17573044 · doi:10.1016/j.biopsych.2007.01.018
7. Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry. 2012;72(7):595-603. PubMed 22658708 · doi:10.1016/j.biopsych.2012.04.028
8. Philip NS, Barredo J, Aiken E, Carpenter LL. Neuroimaging mechanisms of therapeutic transcranial magnetic stimulation for major depressive disorder. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3(3):211-222. PubMed 29486862 · doi:10.1016/j.bpsc.2017.10.007
9. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67(5):507-516. PubMed 20439832 · doi:10.1001/archgenpsychiatry.2010.46
10. Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012;29(7):587-596. PubMed 22689344 · doi:10.1002/da.21969
11. Sackeim HA, Aaronson ST, Carpenter LL, et al. Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation. J Affect Disord. 2020;277:65-74. PubMed 32799106 · doi:10.1016/j.jad.2020.08.005
12. Neuronetics, Inc. NeuroStar clinical evidence (registry clinician-rated CGI-S outcomes and 12-month durability data). https://neurostar.com/hcp/evidence
13. Dunner DL, Aaronson ST, Sackeim HA, et al. A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. J Clin Psychiatry. 2014;75(12):1394-1401. PubMed 25271871 · doi:10.4088/JCP.13m08977
14. Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014-2018). Clin Neurophysiol. 2020;131(2):474-528. PubMed 31901449 · doi:10.1016/j.clinph.2019.11.002

Sackeim 2020 (NeuroStar Outcomes Registry): 83% and 62% are clinician-rated CGI-S results, patient-rated rates were lower. Dunner 2014: 12-month follow-up with continued medication and TMS retreatment available. Individual results may vary.